CD33 and acute promyelocytic leukemia: New drugs, such as FLT3 inhibitors, anti-CD33 monoclonal antibodies and tamibarotene (a synthetic retinoid more potent and less toxic than ATRA) may offer additional options for patients with high-risk or relapsed/refractory APL.